Oncotarget

Research Papers:

Low expression of BMPRIB indicates poor prognosis of breast cancer and is insensitive to taxane-anthracycline chemotherapy

Kun Dai, Fengxia Qin, Huikun Zhang, Xiaoli Liu, Caixia Guo, Ming Zhang, Feng Gu, Li Fu and Yongjie Ma _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:4770-4784. https://doi.org/10.18632/oncotarget.6613

Metrics: PDF 1169 views  |   HTML 2948 views  |   ?  


Abstract

Kun Dai1, Fengxia Qin1, Huikun Zhang1, Xiaoli Liu2, Caixia Guo3, Ming Zhang4, Feng Gu1, Li Fu1, Yongjie Ma2

1Department of Breast Cancer Pathology and Research Laboratory, Key Laboratory of Breast Cancer Prevention and Therapy (Ministry of Education), Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China

2Department of Tumor Cell Biology, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China

3CAS Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China

4Department of Epidemiology and Biostatistics, University of Georgia, Athens, GA, U.S.A

Correspondence to:

Yongjie Ma, e-mail: mayongjie@tjmuch.com

Feng Gu, e-mail: fenggumayo@163.com

Li Fu, e-mail: fulijyb@hotmail.com

Keywords: BMPRIB, breast cancer, bone metastasis, TE chemotherapy, prognosis

Received: September 10, 2015     Accepted: November 26, 2015     Published: December 14, 2015

ABSTRACT

Bone morphogenetic protein receptor type IB (BMPRIB) is one osteogenesis factor, which function in breast cancer has been rarely explored until recently. In the clinical study presented here, involving a cohort of 368 invasive ductal carcinoma (IDC) patients, we identified that patients with low expression of BMPRIB exhibited poor prognosis, especially in the luminal B subtype. We also provided the first piece of evidence that low level of BMPRIB was a promoting factor for breast cancer patients to develop bone metastasis, but not lung, liver or brain. The first of its kind, we reported that patients with high expression of BMPRIB exhibited favorable prognosis by a retrospective analysis consisting of 168 patients treated with TE (taxane and anthracycline) regimens. And the patients with high expression of BMPRIB were more sensitive to TE regimens in the detection of 32 paired pre-neoadjuvant and post-neoadjuvant specimens. Overall, our study concluded that low expression of BMPRIB indicated poor prognosis of breast cancer and was insensitive to taxane-anthracycline chemotherapy. Our findings also lay a foundation to help clinicians improve identification of patients for TE regimens by BMPRIB in the era of precision medicine.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 6613